www.dailymail.com ·
clinton james cancer battle PBS australia drug
Topic context
This topic has been covered 436376 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe recommendation to extend PBS subsidy for Retevmo to MTC patients in Australia is a regulatory decision that directly affects Eli Lilly's revenue from the drug in Australia. If approved, the drug's price will be significantly reduced, expanding patient access but potentially lowering Eli Lilly's per-unit profit. The impact is country-specific (Australia) and affects the pharmaceutical sector, particularly oncology drugs. No direct supply chain or scarcity issues are involved.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- PBAC recommended extending PBS subsidy for Retevmo (selpercatinib) to medullary thyroid carcinoma (MTC) patients in Australia.
- Retevmo costs up to $16,000 per month without subsidy; currently subsidized for lung cancer at $25.
- Approximately 436 Australians are diagnosed with MTC each year.
- PBS listing process may take up to five months, involving negotiations and quality checks.
- Clinton James, a patient advocate, has been pushing for affordable access since 2016.
PBS listing for Retevmo in MTC is a minor event for global healthcare; limited to Australia and one drug.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
- GLOBAL_HEALTHCAREshort
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
local10.com
Trump Administration Announces New Sanctions Against Top Cuban Communist Party Officials
fool.com
Keysight Keys Q2 2026 Earnings Transcript
fool.com
Canaan Can Q1 2026 Earnings Transcript
counterpunch.org
Sanctions Kill I Have Watched Them Do It
morningstar.com